A Systematic Review Of Efficacy And Safety Of Nimodipine On Patients With Diffuse Axonal Injury

Objective This systematic review evaluated the efficacy and safety of nimodipine on patients with diffuse axonal injury(DAI), in order to provide some evidences in treating patients with DAI.Methods A systematic electronic search was carried out to obtain controlled trials before February 2016 from databases which compared the use of nimodipine with control group in patients with DAI. Quality evaluation and data extraction of studies were performed by two investigators independently, and a meta-analysis was performed with the software Review Manager5.3.Results Six low-quality studies and one high-quality studies were included. They involved 688 patients meeting inclusion criteria with 350 in nimodipine group and 338 in control group. Meta-analysis showed that nimodipine could improve the prognosis(RR=1.48,95%CI 为 1.28~1.70,P<0.01),reduce the mortality(RR=0.40,95%CI 为 0.23~0.69,P<0.01)and relieve cerebral vasospasm(WMD:-8.51,95%CI:-11.52~-5.50,P<0.01)of patients with DAI compared to the control group.Conclusion Due to the lack of high-quality and large sample sized randomized controlled trials at home and abroad, the use of nimodipine for treating patients with DAI should be conservatively recommended. To further evaluate the efficacy and safety of nimodipine on patients with DAI, rigorously designed multi-centered randomized controlled trials with large sample sizes about the drug are needed.